EU approves Oxbryta for hemolytic anemia due to sickle cell disease – Global Blood Therapeutics
Global Blood Therapeutics announced the European Commission (EC) has granted Marketing Authorization for Oxbryta (voxelotor) for the treatment of hemolytic anemia due to sickle cell disease (SCD) in… read more.
